Safeguards ostensibly put in place to ensure “a transparent process of development for the DSM,” and an “unbiased, evidence-based DSM, free from any conflicts of interest” have failed to do so. Rather, 69% of DSM-5 task force members have ties to the pharmaceutical industry, an increase of 21% over the proportion of DSM-IV task force members with such ties. Moreover, limits on payments from pharmaceuticals do not apply to research grants. These findings appear in a study published today in PLoS Medicine.
“Nothing has really changed,” says Lisa Cosgrove, one of the study’s authors, in an article in New Scientist, “transparency alone can’t mitigate bias.”
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.